EULAR 2025: SLE & LN Breakthroughs

https://is1-ssl.mzstatic.com/image/thumb/Podcasts122/v4/1c/23/f7/1c23f7d4-d17f-a54a-6112-d5b7a0918696/mza_14361959434911655316.jpg/600x600bb.jpg

The Lupus Academy

41 episodes

6 days ago

The Lupus Academy has been providing accredited education in SLE for healthcare professionals since 2012 and in this monthly podcast Raquel Faria, an Internal Medicine Consultant at the Centro Hospitalar in Porto, will talk with experts from the Lupus Academy Steering Committee about SLE highlights of congresses, we will discuss difficult cases and we have an annual episode where we review all the exciting things that have been happening in lupus that year.

Medicine

Health & Fitness

RSS

All content for The Lupus Academy is the property of The Lupus Academy and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

Medicine

Health & Fitness

https://d3t3ozftmdmh3i.cloudfront.net/production/podcast_uploaded_nologo/28963850/28963850-1664630803407-a63a0b2d419e7.jpg

EULAR 2025: SLE & LN Breakthroughs

The Lupus Academy

47 minutes 24 seconds

3 months ago

EULAR 2025: SLE & LN Breakthroughs

Join us for an in-depth exploration of the most impactful developments presented at the EULAR 2025 Congress, focusing specifically on Systemic Lupus Erythematosus and Lupus Nephritis.

We break down the key takeaways, including:

- New insights into hydroxychloroquine monitoring and glucocorticoid tapering guidance

- "LAMDA," a novel scoring system for lupus arthritis

- Breakthroughs in LN treatment, including the REGENCY trial for obinutuzumab and combinations with existing therapies.

- Updated perspectives on belimumab and anifrolumab, exciting novel therapies in development, and the future of cellular therapies for severe lupus.

Disclaimer: During Lupus Academy podcast episodes, participants may refer to off-label use of medicines for patients with lupus. Lupus Academy does not make anyrecommendations about using a medicine outside the terms of its approved license for use.